Chemopreventive effects of the p53-modulating agents CP-31398 and prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice

Neoplasia (United States)

Volumn 15, Issue 9, 2013, Pages 1018-1027

  Rao, Chinthalapally V ^a   Patlolla, Jagan Mohan R ^a   Qian, Li ^a   Zhang, Yuting ^a   Brewer, Misty ^a   Mohammed, Altaf ^a   Desai, Dhimant ^b   Amin, Shantu ^b   Lightfoot, Stan ^c   Kopelovich, Levy ^d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL) QUINAZOLINE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN DEPENDENT KINASE; CYCLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PRIMA 1; PROTEIN P21; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHROMATIN CONDENSATION; CONTROLLED STUDY; DIET; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG CARCINOGENESIS; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; LUNG NEOPLASMS; MICE; MICE, INBRED A; NITROSAMINES; PYRIMIDINES; RANDOM ALLOCATION; TOBACCO; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884371945     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131256     Document Type: Article

References (46)

1. American Cancer Society (ACS) (2013). Cancer Facts & Figures 2013. American Cancer Society, Atlanta, GA.
2. Reenblatt MS, Bennett WP, Hollstein M, and Harris CC (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54, 4855-4878.
3. Husgafvel-Pursiainen K, Boffetta P, Kannio A, Nyberg F, Pershagen G, Mukeria A, Constantinescu V, Fortes C, and Benhamou S (2000). p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res 60, 2906-2911.
4. Ko LJ and Prives C (1996). p53: puzzle and paradigm. Genes Dev 10, 1054-1072.
5. Giaccia AJ and Kastan MB (1998). The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12, 2973-2983.
6. Lakin ND and Jackson SP (1999). Regulation of p53 in response to DNA damage. Oncogene 18, 7644-7655.
7. Micheal BK and Gerad PZ (2003). Parcing p53 in the cytoplasm. Cell 112, 1-5.
8. El-Deiry WS (1998). Regulation of p53 downstream genes. Semin Cancer Biol 8, 345-357.
9. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, and Beach D (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
10. [Lane DP (1992). p53, guardian of the genome. Nature 358, 15-16.
11. [Vogelstein B and Kinzler KW (1992). p53 function and dysfunction. Cell 70, 523-526.
12. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, and Stark GR (1998). The p53 network. J Biol Chem 273, 1-4.
13. Moll UM, Laquaglia M, Bénard J, and Riou G (1995). Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92, 4407-4411.
14. Issacs JS, Hardman R, Carman TA, Barrnet JC, and Weissman BE (1998). Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines. Cell Growth Differ 9, 545-555.
15. Moos PJ, Edes K, and Fitzpatrick FA (2000). Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci USA 97, 9215-9220.
16. Swamy MV, Herzog CR, and Rao CV (2003). Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 63, 5239-5242.
17. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, and Selivanova G (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8, 282-288.
18. Foster BA, Coffey HA, Morin MJ, and Rastinejad F (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510.
19. Hietanen S, Lain S, Krausz E, Blattner C, and Lane DP (2000). Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 97, 8501-8506.
20. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, and El-Deiry WS (2002). The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1, 47-55.
21. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, and Wiman KG (2005). Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280, 30384-30391.
22. Bullock AN, Henckel J, and Fersht AR (2000). Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245-1256.
23. Wang W, Takimoto R, Rastinejad F, and El-Deiry WS (2003). Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23, 2171-2181.
24. min/+ mice. Cancer Res 68, 7670-7675.
25. Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, and Kopelovich L (2009). Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 69, 8175-8182.
26. Bykov VJN, Issaeva N, Selivanova G, and Wiman KG (2002). Mutant p53 dependent growth suppression distinguishes Prima-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23, 2011-2018.
27. 2-kinase pathway. Mol Cancer Ther 4, 901-909.
28. Stoner GD (1998). Introduction to mouse lung tumorigenesis. Exp Lung Res 24, 375-383.
29. Hecht SS (2005). Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. Carcinogenesis 26, 1488-1492.
30. Hecht SS, Isaacs S, and Trushin N (1994). Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)1-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis 15, 2721-2725.
31. Malkinson AM (1998). Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res 24, 541-555.
32. Malkinson AM (2001). Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer 32, 265-279.
33. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, Fraire AE, Gabrielson EW, Gunning WT, Haines DC, et al. (2004). Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 64, 2307-2316.
34. Kapetanovic IM, Muzzio M, McCormick DL, Thompson TN, Johnson WD, Horn TL, Mohammed A, Rao CV, and Kopelovich L (2012). Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats. Cancer Chemother Pharmacol 69, 1301-1306.
35. Roth JA (2006). Adenovirus p53 gene therapy. Expert Opin Biol Ther 6, 55-61.
36. Peng Z (2005). Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16, 1016-1027.
37. Selivanova G (2010). Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 20, 46-56.
38. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, and Jacks T (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810.
39. Takahashi T, Carbone D, Nau MM, Hida T, Linnoila I, Ueda R, and Minna JD (1992). Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52, 2340-2343.
40. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, and Athar M (2007). CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 117, 3753-3764.
41. Sunday ME, Willett CG, Graham SA, Oreffo VI, Linnoila RI, and Witschi H (1995). Histochemical characterization of non-neuroendocrine tumors and neuroendocrine cell hyperplasia induced in hamster lung by 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone with or without hyperoxia. Am J Pathol 147, 740-752.
42. Khuri FR, Lee JS, Lippman SM, Lee JJ, Kalapurakal S, Yu R, Ro J, Morice RC, Hong WK, and Hittelman WN (2001). Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. Cancer Epidemiol Biomarkers Prev 10, 311-318.
43. Madka V, Zhang Y, Li Q, Mohammed A, Sindhwani P, Lightfoot S, Wu XR, Kopelovich L, and Rao CV (2013). p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII SV40T mice. Neoplasia 15, 966-974.
44. 1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1butanone and phenethyl isothiocyanate. Carcinogenesis 16, 2487-2492.
45. De Flora S, Balansky RM, D'Agostini F, Izzotti A, Camoirano A, Bennicelli C, Zhang Z, Wang Y, Lubet RA, and You M (2003). Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke. Cancer Res 63, 793-800.
46. Wang Y, Zhang Z, Lubet R, and You M (2005). Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. Oncogene 24, 3042-3049.